Artivion | CRY - Cash And Equivalent


Artivion reported $64.91M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Accuray USD 63.34M 5.93M Sep/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Artivion USD 64.91M 8.52M Dec/2025
AtriCure USD 167.43M 19.56M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Inogen USD 106.48M 2.79M Sep/2025
Integra LifeSciences USD 235.05M 2.86M Dec/2025
J&J USD 19.71B 1.48B Dec/2025
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Orthofix International USD 82.02M 19.16M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
ResMed USD 1.42B 33.22M Dec/2025
Stryker USD 4.01B 755M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
Terumo JPY 217.16B 12.86B Sep/2025
Trinity Biotech USD 1.34M 3.83M Sep/2025